Mild cognitive impairment is an early stage of cognitive decline greater than expected for age while most daily functional independence is preserved. It may remain stable, improve, or progress to dementia depending on etiology and risk profile.
FDA approved a subcutaneous starting dose of Leqembi for early Alzheimer's disease. AAIC 2026 real-world data showed most patients stable or improved; a mouse study found KCL-286 repaired DNA damage and reduced inflammation.
A Cochrane review of 17 trials finds amyloid-beta-targeted monoclonal antibodies offer negligible benefit in MCI or mild Alzheimer’s. In a phase 3 trial, the oral agent valiltramiprosate (ALZ-801) showed significant cognitive and functional improvements in the MCI subgroup, with no brain swelling risk. The company plans another phase 3 study in 2026.
Recent studies associate blood biomarkers with brain atrophy and cognitive decline in Alzheimer's disease, while new DNA aptamers, retinal imaging, and speech analysis advance neurodegeneration detection and monitoring.
Studies linked better overall brain health, higher midlife vitamin D levels and lifelong intellectual activity with lower Alzheimer’s-related vulnerability. Findings included lower tau pathology, delayed mild cognitive impairment and dementia onset, and higher cognitive resilience.
A review of more than 200 studies linked up to a third of dementia cases to diseases outside the brain. Trials and broader evidence also support multi-domain prevention strategies.
Research and survey data point to lifelong learning, midlife stimulating activities and treatment of health risks as factors linked to better brain health and lower dementia risk.
January and March 2026 drug pipeline updates included Phase 3 results, Fast Track designations and Priority Review decisions across multiple disease areas. Mavacamten, teplizumab-mzwv, anifrolumab, AXS-05, gedatolisib and AFTX-201 were among the programs with notable milestones.
A study of 2,282 adults aged 60 and older found anemia was associated with higher Alzheimer’s disease blood biomarkers and a 66% higher chance of developing dementia. The highest risk was seen in participants with both anemia and higher biomarker levels.
A major evidence review of 17 clinical trials involving more than 20,000 participants found anti-amyloid Alzheimer’s drugs had absent or trivial effects on cognitive decline and dementia. The review also said the drugs likely increase the risk of brain swelling and bleeding.
A review of 17 studies involving 20,342 patients found anti-amyloid Alzheimer’s drugs had “trivial” effects after 18 months and increased the risk of brain swelling and bleeding. A separate PET study suggested ARIA-E may mark brain regions with greater amyloid plaque reduction.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07773493 |
A Mobile Informatics Solution to Assist Caregivers in Care Coordination and Monitoring Social Engagement |
NOT_YET_RECRUITING | NA |
| NCT07747675 |
Cognitive Intervention for Cognitive Impairment |
NOT_YET_RECRUITING | NA |
| NCT07735910 |
Binaural Beats for Cognitive Function in Older Adults With Mild Cognitive Impairment in Nursing Homes |
RECRUITING | NA |
| NCT07731334 |
Prevalence of Mild Cognitive Impairment and Dementia in Patients Admitted to Non-neurological Rehabilitation Wards |
RECRUITING | NA |
| NCT07729865 |
Maze Activities' Impact on Balance and Gait in Cognitively Impaired Children |
COMPLETED | NA |
| NCT07718945 |
Mental Strategy Training in Mild Cognitive Impairment |
COMPLETED | NA |
| NCT07717567 |
Blood Tests for Alzheimer's Disease: Can Plasma Biomarkers Diagnose and Predict Disease Progression |
RECRUITING | |
| NCT07701785 |
Superior Parietal iTBS for PD-MCI |
RECRUITING | NA |
| NCT07690384 |
Effects of Functional Oils on Obesity With Mild Cognitive Impairment |
NOT_YET_RECRUITING | NA |
| NCT07685067 |
LifeBio Memory: Development of a Reminiscence Therapy Online Platform With Machine Learning to Increase Engagement |
NOT_YET_RECRUITING | NA |
